The BCR-ABL1 fusion gene is the molecular marker of chronic myeloid leukemia (CML). The e19a2 transcript is a rare variant associated with various clinical presentations and courses of CML. We herein present a case of e19a2-positive CML who was intolerant to initial treatment with imatinib and successfully responded to subsequent nilotinib therapy. She achieved a major molecular response and has since be able to sustain it. According to the literature, achieved molecular response by imatinib monotherapy has not yet been reported in e19a2-positive CML patients. Second generation tyrosine kinase inhibitors may therefore be a more effective treatment for e19a2-positive CML patients.
Introduction
The BCR-ABL1 fusion gene, generated by a reciprocal chromosomal translocation t(9;22)(q34;q11.2), resulting in the Philadelphia (Ph)-chromosome, is the molecular marker of chronic myeloid leukemia (CML) (1) . Various BCR-ABL1 transcripts have been described and the majority of CML patients express either the e13a2 or e14a2 BCR-ABL1 transcript which encodes a p210 fusion protein. The e19a2 transcript, also called μ-BCR-ABL1, is a rare transcript which encodes a p230 fusion protein associated with various clinical presentations and courses of CML (1) (2) (3) (4) . Recent studies using multiplex reverse-transcriptase polymerase chain reaction (RT-PCR) methods reported that the e19a2 transcript was observed in 0.7-2.7% of patients with Phpositive CML (5, 6) .
Since e19a2 was initially described in 1990 by Saglio et al. (1) , approximately fifty cases of e19a2 BCR-ABL1 CML have been reported in the literature. While tyrosine kinase inhibitor (TKI) therapy is considered to be the optimal frontline treatment for CML with quantitative molecular responses predictive of overall and progression-free survival (7), the efficacy of TKI for treating e19a2 CML has not yet been established due to insufficient clinical experiences.
We herein described a Ph-positive CML patient with the e19a2 variant who was intolerant to imatinib therapy and obtained a remarkable molecular response to subsequent nilotinib therapy. A diagnosis of e19a2-positive chronic phase CML was made and imatinib (400 mg QD) treatment was started. She rapidly achieved a hematological response; however, due to grade 3 cytopenia (thrombocyte and neutrophil) and grade 2 edema, imatinib treatment was interrupted and re-started at 200 mg QD. Despite the imatinib dose modification, the patient's grade 3 neutropenia persisted. The National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (8) were used to grade toxicities. In July 2009, the patient achieved a complete cytogenetic response (CCyR); however, she developed febrile neutropenia and diverticulitis. Although the reduced dosage of imatinib (100 mg QD) was tolerable, she lost her CCyR in February 2010 (Figure) . The search for a mutation on the ABL1 gene was carried out via the PCR-Invader assay at BML, INC (Tokyo, Japan) as previously described (9) and no mutation was detected.
Therefore, the patient's therapy was changed to nilotinib (400 mg QD). She achieved CCyR after 3 months of treatment and no remarkable toxicity due to nilotinib was observed ( Figure) . In order to evaluate the depth of the molecular response, the e19a2 mRNA transcript level was measured via the RQ-PCR assay at BML, INC as previously described (10) . After 9 months of nilotinib treatment, a remarkable reduction in the e19a2 transcript level (-5.42 log) from baseline was seen. The patient has maintained this reduction (>5 log) for 36 months following nilotinib administration (Table 1) .
Discussion
The e19a2 subtype was originally associated with a neutrophilic phenotype and a relatively indolent clinical course but has been more recently described in classical CML in all phases (1) (2) (3) (4) . Although the efficacy of imatinib for e19a2-positive CML has been reported, most cases are limited to the cytogenetic response. According to the literature, 11 cases (including our patient) have been treated with imatinib in the chronic phase (Table 2) (11-18). There are no reported cases of CML patients who achieved molecular response through imatinib monotherapy. Conversely, second generation TKIs have been shown to be effective for a few e19a2-positive CML patients with documented acquired resistance due to ABL1 kinase domain mutations (Table 3) (13, (15) (16) (17) (18) , whereas the efficacy for imatinibintolerant e19a2-positive CML is not clear.
Nilotinib is a potent and selective second generation inhibitor of BCR-ABL; it has a higher binding affinity for (20, 21) , making it less susceptible to point mutations due to a different topological fit in the kinase active site. Cortes et al. previously reported that cross-intolerance to nilotinib in imatinib-intolerant patients with CML is infrequent, particularly for patients with nonhematologic adverse events, which is the most common reason for imatinib intolerance (22) . This minimal crossintolerance resulted in more patients achieving the planned nilotinib doses and translated into significant clinical responses. The ENESTnd, a prospective and randomized study, showed an initial advantage of nilotinib over imatinib when they were used as front-line treatment (23) . Interestingly, two very recent reports showed that e19a2-positive CML patients who received front-line nilotinib therapy achieved molecular responses (Table 3) (19, 24) .
In our case, the treatment interruption and dose reduction of imatinib were necessary due to the grade 3 cytopenia and grade 2 edema. After switching to nilotinib therapy, both adverse events were improved or disappeared. The dose of 400 mg BID was initially planned, however, the patient requested 400 mg QD. Despite the dose reduction, the patient achieved molecular response, obtaining a greated than 5 log reduction in the e19a2 transcript level and has maintained this reduction.
Although the reports on e19a2-positive CML treated with TKI is limited to small case series and anecdotal reports, the lack of a molecular response following imatinib therapy and the favorable response to second generation TKI therapy in our patient suggest that e19a2-positive CML may respond better to initial treatment with second generation TKI. In addition, the present case suggests that nilotinib may be a promising choice for imatinib-intolerant e19a2-positive CML.
In initial publications regarding the mechanism of imatinib against BCR-ABL positive CML cells, imatinib was reported to suppress the cell growth of p230 BCR-ABL positive CML cell lines as well as p210 positive cells (25) . However, the mechanism of second generation TKI on p230 BCR-ABL cells has not yet been established.
A larger case study and further investigation of the mechanism of nilotinib treatment on e19a2-positive CML may help to clarify the responsiveness of e19a2-positive CML to second generation TKI therapy and to establish the optimal therapeutic strategy for future cases.
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